Psilocybin microdosing: research overview, UK legality, and why we don't dose

Psilocybin microdosing, taking sub-perceptual doses (typically 1/10 to 1/20 of a recreational dose) of psilocybin-containing mushrooms, has become one of the most-discussed cognitive enhancement practices online. The trial evidence is modest and largely negative on the strongest claims; the UK legal context is severe.

This page describes what the research shows and the regulatory reality. It does not provide dosing, sourcing, or how-to information.

UK legal status#

Psilocybin and psilocin are Class A controlled drugs under the Misuse of Drugs Act 1971. Possession carries a maximum 7-year prison sentence; supply carries a maximum life sentence. Growing psilocybin-containing mushrooms is a Class A offence.

This is the most serious drug-control classification in UK law, the same class as heroin and cocaine.

A handful of UK clinical trials use psilocybin under strict Home Office licensing for specific research purposes (predominantly treatment-resistant depression). These are tightly controlled clinical settings; participation requires meeting trial inclusion criteria and is not a route to personal supply.

What the controlled trial evidence shows on microdosing#

The microdosing literature is dominated by:

Self-report studies. Online surveys of microdosers report subjective improvements in mood, focus, and creativity. These are uncontrolled and subject to massive selection bias; people who liked microdosing are more likely to fill in surveys.

Placebo-controlled microdose trials. Several have now been published. The pattern is striking:

• Szigeti et al. 2021 (Imperial College London): large self-blinded study; both placebo and microdose groups reported subjective improvements. Differences between groups were small or absent.
• Cavanna et al. 2022 — similar pattern; subjective effects but minimal placebo-controlled difference.
• Smaller lab studies have shown modest effects on specific cognitive tasks, with substantial heterogeneity.

The summary: most of what microdosers report subjectively is likely placebo effect plus general life-attention from running an experiment on yourself.

What the macro-dose psilocybin trials show#

Distinct from microdosing, the macro-dose psilocybin literature for treatment-resistant depression has produced more positive results. These trials use single or repeated supervised doses of 25 mg psilocybin in clinical settings with psychotherapy support. They are not what microdosers are doing.

The Compass Pathways Phase 3 trials and academic trials in TRD have shown clinically meaningful effects on depression scales. Whether psilocybin will become a licensed medicine in the UK is an open regulatory question.

What gets dangerously overstated in microdosing discourse#

• "Safe, no side effects." Trial data show effects on heart rate, anxiety in some users, and unmasking of psychiatric vulnerabilities including psychosis in susceptible individuals.
• "Improves all mental health conditions." Not supported.
• "Tested and proven safe." Long-term safety data on chronic microdosing is essentially absent.
• "Legal grey area." False in the UK. Psilocybin is unambiguously Class A.

Specific safety considerations#

For people considering psilocybin in any form, several conditions are absolute contraindications in clinical trials:

• Personal or family history of psychosis or bipolar disorder
• Active or untreated psychiatric instability
• Cardiovascular conditions, particularly uncontrolled hypertension
• On SSRIs / SNRIs (serotonin syndrome risk theoretically; mostly empirical caution)
• On MAOIs
• Pregnancy or breastfeeding
• Under 18

These exclusion criteria exist for good reasons.

What we'd actually say#

We don't provide microdosing dosing, sourcing, or how-to information.

For someone with treatment-resistant depression interested in clinical psilocybin therapy, the route is clinical trial participation through legitimate research centres (Imperial College London, King's College London, and a small number of others). Compass Pathways and similar commercial programmes will eventually offer licensed treatment if regulatory approval lands.

For someone seeking cognitive enhancement, the placebo-controlled microdose trial evidence is weak. There are better-evidenced approaches: sleep, exercise, caffeine + L-theanine, and the evidence-supported interventions we cover elsewhere.

The legal risk in the UK is severe. The clinical evidence base for microdosing specifically is thin.

When to talk to a clinician#

• Treatment-resistant depression: discuss specialist psychiatry referral and current research
• Significant mental health symptoms: start with NICE-recommended first-line treatments
• Personal or family history of psychosis or bipolar
• On psychiatric medications (SSRIs, MAOIs, lithium, antipsychotics): significant interaction risks
• Any reaction or adverse experience after psilocybin use: clinical care is paramount; the legal framing is separate